May 18, 2017 9:00 am EDT A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q(TM) assays
May 11, 2017 6:30 am EDT VolitionRx Limited Announces First Quarter 2017 Financial Results and Business Update
May 8, 2017 8:00 am EDT VolitionRx Limited Schedules First Quarter 2017 Earnings Conference Call and Business Update
Apr 27, 2017 7:46 am EDT Volition makes progress with its Colorectal Cancer Screening Triage Test in both Asia and Europe
Apr 21, 2017 8:26 am EDT Volition opens a new Research and Development facility in Belgium with a state of the art, purpose-built laboratory
Mar 28, 2017 4:01 pm EDT Volition America, Inc. Retains Strategic Expert in Securing Non-Dilutive Funding Opportunities in the United States
